BIOPARTNERS' BIOSIMILAR DRUG KNOCKED BACK IN EUROPE

A A

BioPartners has failed to bring its second biosimilar product into Europe after the European Agency for the Evaluation of Medicinal Products (EMEA) issued a negative opinion on its hepatitis C drug, citing characterisation, manufacturing and quality control concerns.
In-PharmaTechnologist.com